The Lantern Project will screen for patients who may be suffering from Gaucher disease, Fabry disease, Pompe disease, MPS I, or ASMD, and offer confirmatory DNA testing.
In PNAS this week: DNA vaccine-based approach for Duchenne muscular dystrophy tested in mice, antimicrobial found in bear saliva, and more.
Stat News reports federal regulators have halted Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy trial.
The effort, sponsored by two therapeutics companies, is providing no-cost genetic testing and counseling for people with Duchenne who otherwise couldn't afford it.
In Science this week: gene variant linked to inflammatory bowel disease, and more.
The researchers found that it's not necessary to design individual guide RNAs for each DMD mutation or excise large genomic regions with pairs of guide RNAs.
The Salk Institute-led team developed a system for in vivo activation of endogenous target genes through trans-epigenetic remodeling.
AmCare Genomics said that it has a large network that would enable it to raise awareness about Genomic Vision's test for facioscapulohumeral muscular dystrophy.
In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.
In Science this week: two proteins may help treat muscular dystrophy, and more.
NPR reports that with medical data being big business, some companies want to get patients involved.
The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.
In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.